Scisparc-clearmind collaboration leads to filing of international patent application for novel treatment of anorexia, bulimia and other eating disorders

Tel aviv, israel, april 25, 2025 (globe newswire) -- scisparc ltd. (nasdaq: sprc) (the "company" or "scisparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with clearmind medicine inc. (nasdaq: cmnd) has led to the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders.
SPRC Ratings Summary
SPRC Quant Ranking